Dr. Reddy’s and Immutep Forge Strategic Partnership for Eftilagimod Alfa
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an update.
On December 8, 2025, Dr. Reddy’s Laboratories announced a strategic collaboration and exclusive licensing agreement with Immutep SAS to develop and commercialize Eftilagimod Alfa, a novel cancer immunotherapy, outside North America, Europe, Japan, and Greater China. This agreement allows Dr. Reddy’s to expand its oncology portfolio by leveraging its market access and expertise to advance Eftilagimod Alfa’s development, while Immutep will receive an upfront payment of USD 20 million and potential milestone payments. The collaboration underscores Dr. Reddy’s commitment to delivering innovative cancer treatments and positions the company to enhance its impact in global oncology markets.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories has a strong financial foundation and strategic growth initiatives, but faces challenges in the U.S. generics market and regulatory issues. The technical indicators suggest a bearish trend, and the valuation is reasonable but not compelling. The mixed sentiment from the earnings call reflects both opportunities and risks.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a prominent pharmaceutical company based in Hyderabad, India, known for its focus on developing and delivering innovative therapies, particularly in the field of oncology. The company engages in the production and commercialization of a wide range of pharmaceutical products, including active pharmaceutical ingredients, generic formulations, and biosimilars, with a strong market presence in India and emerging markets.
Average Trading Volume: 1,042,818
Technical Sentiment Signal: Buy
Current Market Cap: $11.82B
See more insights into RDY stock on TipRanks’ Stock Analysis page.
